Today, we make history... again! The FDA has officially approved Gomekli (mirdametinib) - the second-ever…
Childrens Tumor FoundationFebruary 11, 2025
NF affects 1 in every 2,000 births
NF refers to genetic conditions that cause tumors to grow on nerves throughout the body. NF includes all forms of neurofibromatosis and schwannomatosis and affects about 4 million people worldwide. Anyone can be born with NF, and it affects everyone differently. There is no cure yet.
2
FDA-approved drugs for NF, and more are being researched
Koselugo (selumetinib) and Gomekli (mirdametinib). are the only FDA-approved drugs for NF1. CTF-funded research paved the way for these approvals.
3X
the number of NF clinical trials in the past 10 years
There are currently 67 active clinical trials for NF – three times the number of trials than just ten years ago!
47
years of funding NF research
The Children’s Tumor Foundation was founded nearly 50 years ago as the first grassroots organization to support patients with all types of NF.
11,000
have joined the NF Registry
The NF Registry is a secure website where people with NF can take an active role in the search for better treatments.
20,000
patients each year visit the NF Clinic Network
The NF Clinic Network (NFCN) is the first nationwide network focused on enhancing clinical care and best practices for NF treatment.
CTF Knowledge Base
What are you looking for?
Search our website for news and information about NF.
Latest News
From NF to the World: Rare Disease Day and the Race for Faster Treatments
This has been a February to remember! In just a few weeks, a new drug…
Ensuring NF Research is Our Priority in Washington, DC
CTF is steadfast in advocating for federal research funding that drives progress for NF patients.…
From NF to the World: Rare Disease Day and the Race for Faster Treatments
This has been a February to remember! In just a few weeks, a new drug…
Healx Announces First Patient Dosed in Phase 2 Trial Evaluating HLX-1502 for the Treatment of NF1
Healx has dosed the first patient in its Phase 2 trial for HLX-1502 - the…
Ensuring NF Research is Our Priority in Washington, DC
CTF is steadfast in advocating for federal research funding that drives progress for NF patients.…
Sign Up for our Newsletter
Join our mailing list for news, exclusive resources, events and opportunities.
"*" indicates required fields
